Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MedImmune -- Ignore unavailable to you. Want to Upgrade?

To: A.J. Mullen who wrote (349)	11/29/2004 9:43:53 AM
From: scaram(o)uche	Read Replies (1) \| Respond to of 416

Ashley: Amevive isn't selling, so it's probably moot. Just consider it venting by a disgruntled.... observer? It's all in the BTRN thread. IMO, the company (MEDI) misrepresented a dose-exploration study in humans, forcing the reported interpretation to fit preconception (an alternative is that they were lying through cheating teeth, imo). The particular CD2 epitope in question is only expressed by gorillas and humans, so the issue will never be settled short of initiating additional human trials, and that isn't going to happen. Rick